State Street Corp Cyteir Therapeutics, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.71 - $2.84 $60,433 - $63,332	22,300 Added 93.49%	46,153 $131,000
Q2 2022 Aug 15, 2022	SELL	$1.62 - $4.4 $182,504 - $495,690	-112,657 Reduced 82.53%	23,853 $71,000
Q1 2022 May 16, 2022	BUY	$3.39 - $10.51 $73,569 - $228,088	21,702 Added 18.9%	136,510 $515,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $225,274 - $440,235	22,917 Added 24.94%	114,808 $1.31 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $1.34 Million - $2.01 Million	91,891 New	91,891 $1.61 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.